Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Abstract

This review article discusses PET agents, other than (18)F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-(18)F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-(18)F-fluoro-3'-deoxythymidine and (18)F-1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as (60/62/64)Cu-labeled diacetyl-bis(N(4)-methylthiosemicarbazone) and (18)F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, l-[methyl-(11)C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16beta-(18)F-fluoro-5alpha-dihydrotestosterone and 16alpha-(18)F-fluoro-17beta-estradiol, respectively.

DOI: 10.2967/jnumed.108.057281
0204060200920102011201220132014201520162017
Citations per Year

123 Citations

Semantic Scholar estimates that this publication has 123 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Dunphy2009RadiopharmaceuticalsIP, title={Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.}, author={Mark P. S. Dunphy and Jason S Lewis}, journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine}, year={2009}, volume={50 Suppl 1}, pages={106S-21S} }